NCT01004003 - Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter

Enrollment

125

Participants

Timeline

Start Date

October 22, 2009

Primary Completion Date

July 14, 2014

Study Completion Date

October 12, 2016

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Sorafenib

DRUG

BIBF 1120

Dose escalated in phase I until MTD or adjusted by investigator, dose in phase II part based on phase I data

Trial Locations (28)

1199.37.43001 Boehringer Ingelheim Investigational Site, Vienna

1199.37.43002 Boehringer Ingelheim Investigational Site, Vienna

1199.37.33001 Boehringer Ingelheim Investigational Site, Paris

1199.37.33002 Boehringer Ingelheim Investigational Site, Paris

1199.37.49008 Boehringer Ingelheim Investigational Site, Berlin

1199.37.49009 Boehringer Ingelheim Investigational Site, Erlangen

1199.37.49002 Boehringer Ingelheim Investigational Site, Freiburg im Breisgau

1199.37.49001 Boehringer Ingelheim Investigational Site, Hanover

1199.37.49010 Boehringer Ingelheim Investigational Site, Heidelberg

1199.37.49005 Boehringer Ingelheim Investigational Site, Jena

1199.37.49004 Boehringer Ingelheim Investigational Site, Magdeburg

1199.37.49003 Boehringer Ingelheim Investigational Site, München

1199.37.49006 Boehringer Ingelheim Investigational Site, Tübingen

1199.37.36001 Boehringer Ingelheim Investigational Site, Debrecen

1199.37.31002 Boehringer Ingelheim Investigational Site, Leiden

1199.37.31001 Boehringer Ingelheim Investigational Site, Utrecht

1199.37.48002 Boehringer Ingelheim Investigational Site, Olsztyn

1199.37.48001 Boehringer Ingelheim Investigational Site, Warsaw

1199.37.48003 Boehringer Ingelheim Investigational Site, Warsaw

1199.37.40002 Boehringer Ingelheim Investigational Site, Bucharest

1199.37.40003 Boehringer Ingelheim Investigational Site, Cluj-Napoca

1199.37.44001 Boehringer Ingelheim Investigational Site, Edgbaston, Birmingham

1199.37.44005 Boehringer Ingelheim Investigational Site, Glasgow

1199.37.44008 Boehringer Ingelheim Investigational Site, Liverpool

1199.37.44002 Boehringer Ingelheim Investigational Site, London

1199.37.44003 Boehringer Ingelheim Investigational Site, London

1199.37.44006 Boehringer Ingelheim Investigational Site, Manchester

1199.37.44004 Boehringer Ingelheim Investigational Site, Nottingham